News/ News/ R&D Bad news for Biohaven as verdiperstat flunks first phase 3 test Phil Taylor Biohaven Pharmaceuticals, multiple system atrophy, neurodegenerative disease, rare disease, verdiperstat 0 Comment Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological Share X Bad news for Biohaven as verdiperstat flunks first phase 3 test https://pharmaphorum.com/news/bad-news-for-biohaven-as-verdiperstat-flunks-first-phase-3-test/